Article: CAR-T Cell Therapy for Follicular Lymphomas.
Mediterranean journal of hematology and infectious diseases
2024 Volume 16, Issue 1, Page(s) e2024012
Abstract: Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will ... ...
Abstract | Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients. |
---|---|
Language | English |
Publishing date | 2024-01-01 |
Publishing country | Italy |
Document type | Journal Article ; Review |
ZDB-ID | 2674750-9 |
ISSN | 2035-3006 |
ISSN | 2035-3006 |
DOI | 10.4084/MJHID.2024.012 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.